CAMRF (Camurus AB) Minority Interest : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Camurus AB Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Camurus AB's minority interest for the quarter that ended in Sep. 2024 was $0.00 Mil.

Camurus AB Minority Interest Historical Data

The historical data trend for Camurus AB's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camurus AB Minority Interest Chart

Camurus AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Minority Interest

Get a 7-Day Free Trial

Camurus AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Minority Interest	Get a 7-Day Free Trial															-	-	-	-	-

Camurus AB Minority Interest Calculation

Camurus AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (OTCPK:CAMRF) » Definitions » Minority Interest

Comparable Companies

Traded in Other Exchanges

CAMX:Sweden CAMXs:UK 0RD1:UK 7CA:Germany

Address

Ideon Science Park, Lund, SWE, SE-223 70

Website

https://www.camurus.com

Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.